There is no doubt that Lineage Cell Therapeutics Inc (LCTX) ticks all the boxes.

With 0.76 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.6 million shares. The 52-week range on LCTX shows that it touched its highest point at $1.61 and its lowest point at $0.48 during that stretch. It currently has a 1-year price target of $4.50. Beta for the stock currently stands at 1.27.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of LCTX was down-trending over the past week, with a drop of -1.31%, but this was up by 0.15% over a month. Three-month performance dropped to -23.12% while six-month performance fell -22.33%. The stock lost -37.98% in the past year, while it has gained 34.53% so far this year. A look at the trailing 12-month EPS for LCTX yields -0.11 with Next year EPS estimates of -0.10. For the next quarter, that number is -0.03. This implies an EPS growth rate of 8.33% for this year and 7.58% for next year. EPS is expected to grow by 9.14% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 19.25%.

Float and Shares Shorts:

At present, 220.42 million LCTX shares are outstanding with a float of 219.45 million shares on hand for trading.

Analysts Ratings:

In the same way, a target price assigned to a stock can also reveal much about its potential.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.00299246 being high and -$0.10083 being low. For LCTX, this leads to a yearly average estimate of -$0.05191123. Based on analyst estimates, the high estimate for the next quarter is -$0.04 and the low estimate is -$0.04. The average estimate for the next quarter is thus -$0.04.